Eledon Pharmaceuticals, Inc.
monoclonal antibodies and immunomodulatory therapeutics for transplant rejection and organ preservation
- Sector
- Biotech
- Headquarters
- IRVINE, CA
- Latest Form D
- $50M, May 2024
- Total capital
- $227M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $227M
- 8 Form D · last May 2024
- 29 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 14 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$50M
- Private capital raisedForm D · SEC · 7th filing$35M
- Private capital raisedForm D · SEC · 6th filing$108M
- Private capital raisedForm D · SEC · 5th filing$862K
- Private capital raisedForm D · SEC · 4th filing$862K
- Private capital raisedForm D · SEC · 3rd filing$20M
- Private capital raisedForm D · SEC · 2nd filing$1.9M
- Private capital raisedForm D · SEC · 1st filing$10M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Allan KirkDirectorNamed in SEC Form D filings
- Bryan SmithExecutive OfficerNamed in SEC Form D filings
- David-Alexandre GrosExecutive Officer, DirectorNamed in SEC Form D filings
- Gary LyonsDirectorNamed in SEC Form D filings
- James RobinsonDirectorNamed in SEC Form D filings
- Jan HillsonDirectorNamed in SEC Form D filings
Show all 12 people
- John McBrideDirectorNamed in SEC Form D filings
- June LeeDirectorNamed in SEC Form D filings
- Keith KatkinDirectorNamed in SEC Form D filings
- Paul LittleExecutive OfficerNamed in SEC Form D filings
- Steven PerrinExecutive Officer, DirectorNamed in SEC Form D filings
- Walter OgierDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 14- PendingMethods For The Treatment Of Amyotrophic Lateral SclerosisUSPTOApplication 18870287
- PendingCompositions And Methods For Otologic Prophylaxis And TreatmentUSPTOApplication 15365321
- PendingMethods For The Treatment Of Kidney Diseases Or DisordersUSPTOApplication 18870289
Show all 14 patent records
- Methods For The Treatment Of Amyotrophic Lateral SclerosisOct 30, 2025 · Application 18870287Pending
- Compositions And Methods For Otologic Prophylaxis And TreatmentJun 1, 2017 · Application 15365321Pending
- Methods For The Treatment Of Kidney Diseases Or DisordersApplication 18870289Pending
- Methods And Compositions For Prevention Of Transplant RejectionApplication PCTUS2024057894Pending
- Use Of ANTI-CD40 Ligand Antibodies For Immunosuppression In Islet Cell TransplantationApplication 63713013Pending
- Methods And Compositions For Prevention Of Transplant RejectionApplication 63643866Pending
- Methods And Compositions For Treating Kidney DisordersApplication 63603591Pending
- Methods For The Treatment Of Amyotrophic Lateral SclerosisApplication PCTUS2023067438Pending
- Methods For The Treatment Of Kidney Diseases Or DisordersApplication PCTUS2023067424Pending
- Methods For The Treatment Of Amyotrophic Lateral SclerosisApplication 63365458Pending
- Methods For The Treatment Of Kidney Diseases Or DisordersApplication 63365448Pending
- Use Of ANTI-CD40 Ligand Antibodies For Immunosuppression In Islet Cell TransplantationApplication PCTUS2025028223Pending
- Methods And Compositions For Treating Kidney DisordersApplication 19591501Pending
- Methods And Compositions For Prevention Of Transplant RejectionApplication PCTUS2025028248Pending
Related companies, and why
- Inflammasome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Terns Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Stoke TherapeuticsSimilar federal contract value in Biotech · null in contracts
- VBI Vaccines Inc/BCSimilar federal contract value in Biotech · null in contracts
- AUKERA, INC.Similar federal contract value in Biotech · null in contracts
- Vivodyne, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .